From: Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran
Treatment
Relative risk (95.0% CI)
Placebo risk (95.0% CI)
LDX
3.21 (0.93–7.90)
0.0443 (0.035–0.053)
ATX
2.67 (1.68–4.13)
MPH-ER
2.76 (1.83–4.07)